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Nonalcoholic fatty liver disease (NAFLD) is prevalent in 20–25% of the general population and is associated with metabolic risk
factors such as obesity, diabetes mellitus, and dyslipidemia. Histologically, NAFLD ranges from simple steatosis to nonalcoholic
steatohepatitis (NASH), fibrosis, and cirrhosis. As NASH develops in only 10–15% of patients with NAFLD, it is not practical
to biopsy all patients who present with NAFLD. Noninvasive fibrosis tests have been extensively developed recently and offer
alternatives for staging fibrosis. Despite their increasing use, such tests cannot adequately differentiate simple steatosis fromNASH.
At present, such tests can be used as first line tests to rule out patients without advanced fibrosis and thus prevent unnecessary
secondary care referrals in a significant number of patients. In this review we present the evidence for the use of noninvasive
fibrosis tests in patients with NAFLD.
1. Introduction
Nonalcoholic fatty liver disease (NAFLD) is the most com-
mon cause of abnormal liver function tests in primary
care in industrialized countries. It is associated with insulin
resistance (IR) and is considered as the hepatic manifestation
of the metabolic syndrome (MeS) [1].
The reported prevalence ofNAFLDvarieswidely depend-
ing on the studied population, the diagnostic modality, and
the definition [2]. According to the latest data, 20–30% of
European and Middle East population have NAFLD, with an
incidence of 39/100.000 inhabitants in the UK [3]. In USA the
prevalence ofNAFLD as assessed byMR spectroscopy is 34%,
while it is lower in the Far East (15%) [4].
Ultrasonography, in association with routine laboratory
investigations, is an acceptable first line test to identify
patientswithNAFLD, even if it has suboptimal sensitivity and
reproducibility, being an operator-dependent technique [4].
From a histological point of view, NAFLD encompasses
a wide spectrum of liver pathology, from simple steatosis
to steatohepatitis, fibrosis, and cirrhosis [5]. While simple
steatosis is associated with a low risk of progression, patients
with NASH, estimated to be 15–20% of the NAFLD popula-
tion, have increased risk of liver-related morbidity and mor-
tality from cirrhosis and development of HCC [6, 7]. Other
metabolic risk factors, such as the presence of metabolic
syndrome, are associated with more severe liver disease [8].
The pivotal issue in the management of patients with
NAFLD is the diagnosis of steatohepatitis and fibrosis at
an early stage. This would allow the identification of those
patientswho require stricter follow-up, targeted lifestyle inter-
ventions for weight reduction, management of the compo-
nents of the metabolic syndrome, and eventual inclusion in
trials of new treatment strategies [9].
Liver biopsy is the gold standard for diagnosing NASH
and assessing fibrosis, though its limitations are well known:
potential risk of sampling errors, intra- and interobserver
variability, invasiveness, and scarce tolerability by the patient
[10, 11]. These characteristics, together with the high preva-
lence of hepatic steatosis and its low risk of progression in the
majority of affected people, make liver biopsy an inappropri-
ate first line tool for diagnosis in unselected patients.
Noninvasive liver fibrosis tests have been extensively
developed recently and offer alternatives for staging fibrosis.
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Table 1: Noninvasive fibrosis serum tests and scores to diagnose nonalcoholic steatohepatitis (NASH) and/or stage fibrosis in patients with
nonalcoholic fatty liver disease (NAFLD) [12].
Test Variables NAFLD stage assessed Cut-off AUROC
AST : ALT ratio ALT and AST serum levels F4 1 NA
CK-18 Cytokeratin 18 fragments
NAFLD
NASH
Fibrosis (any degree)
NA
0.77
0.65–0.83
0.68
Ferritin Serum ferritin NASH/≥F2
≥F3
1.5 ULN
2.5 ULN
0.57
NA
NASH
diagnostic CK-18 fragments, adiponectin, and resistin NASH 0.43 0.70–0.85
NASH
diagnostic panel
Gender, BMI, diabetes, triglycerides, and
CK-18 (total levels and fragments) NASH NA 0.81
NashTest
Age, gender, weight, height, bilirubin, GGT,
𝛼2-macroglobulin, apolipoprotein A1,
haptoglobin, AST, serum glucose,
triglycerides, and cholesterol
No NASH
Borderline NASH
NASH
NA
NA
NA
0.69–0.83
NAFIC scoring
system
Ferritin ≥200 or ≥300 ng/mL (F or M) = 1
Serum fasting insulin ≥10𝜇U/mL = 1
Serum type IV collagen 7s ≥5.0 ng/mL = 2
NASH 2 0.78–0.85
Modified
NAFIC
scoring system
Ferritin ≥200 or ≥300 ng/mL (F or M) = 1
Serum fasting insulin ≥10 < 15 𝜇U/mL = 1
Serum fasting insulin ≥15 = 2
Serum type IV collagen 7s ≥5.0 ng/mL = 2
NASH 2 0.80
PIIINP Terminal peptide of procollagen III levels NASH
≥F3
6.6 ng/mL (low cut-off)
11 ng/mL (high cut-off)
0.82
0.84
APRI AST, PLT ≥F2 0.45 (low cut-off)1.5 (high cut-off) 0.62–0.94
BARD BMI, AST/ALT ratio, and diabetes ≥F3 ≥2 0.80
BARDI BMI, AST/ALT ratio, diabetes, and INR ≥F3 ≥3 0.88
NAFLD fibrosis
score
Age, BMI, diabetes. AST, ALT, platelet
count, and albumin ≥F3
−1.45 (low cut-off)
0.67 (high cut-off) 0.82–0.88
FIB-4 Age, AST, ALT, and platelet count ≥F3 1.3–1.92 (low cut-off)3.25 (high cut-off) 0.87, 0.88
Hepascore Age, sex, bilirubin, GGT, 𝛼2-macroglobulin,and hyaluronic acid
≥F2
≥F3
F4
0.44
0.37
0.7
0.73
0.81
0.9
ELF test Hyaluronic acid (HA), PIIINP, and tissueinhibitor of metalloproteinase 1 (TIMP-1).
≥F2
≥F3
F4
8.5–10.18
10.35 (9.33–10.51)
9.35–11.3
0.82
0.90
0.87
FibroTest Haptoglobin, 𝛼2-macroglobulin,apolipoprotein-A, bilirubin, and GGT ≥F3
0.3 (low cut-off)
0.7 (high cut-off) 0.88
FibroMeter Age, weight, glucose, AST, ALT, PLT, andferritin
≥F2
≥F3
F4
F3: 0.61 (low cut-off)
0.71 (high cut-off)
0.94
0.93
0.9
ALT: alanine aminotransferase; AST: aspartate aminotransferase; AUROC: area under receiver operator characteristic curve; CK-18: cytokeratin 18; NA: not
available; BMI: bodymass index; GGT: 𝛾-glutamyl transpeptidase; PLT: platelets; PIIINP: terminal peptide of procollagen III; APRI: aspartate aminotransferase
to platelets ratio; INR: international normalized ratio; ELF: enhanced liver fibrosis; ULN: upper limit of normal.
In this review, we discuss the evidence for their use in patients
with NAFLD.
2. Noninvasive Fibrosis Tests
In the last years, we have witnessed explosive development
and use of noninvasive fibrosis tests (Table 1). These can
be divided into three categories, namely, simple or indirect
serum markers, direct serum markers, and imaging modali-
ties [13].
(i) Indirect or class II serum markers consist of rou-
tine biochemical tests such as transaminases, platelet count,
and albumin that are usually combined with demographic
characteristics potentially linked to liver fibrosis such as age
or diabetes [14].
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Indirect serummarkers and panels usually have dual cut-
offs: a high cut-off with high specificity and a low cut-off with
high sensitivity. If these cut-offs are combined, depending
on the clinical scenario and prevalence of the examined
disease, the numbers of false positive and false negatives are
minimized. However, a proportion of patients will fall in the
indeterminate range of values and will therefore need further
testing.
(ii) Direct or class I serum markers detect the fibrogenic
process and the extracellular matrix turnover. Such markers
include hyaluronic acid, collagenases and their inhibitors
(TIMP), and profibrotic cytokines (TGF beta) [15]. Although
they perform better than indirect serum markers, their
sensitivity is low in the initial stages of fibrosis and they are
not routinely available in most clinical laboratories [14].
(iii) Imaging modalities measure the elasticity and/or
stiffness of the liver tissue with MR and US techniques.
Transient elastography (Fibroscan, Echosens, Paris,
France) is a noninvasive US-based technique in which a low-
frequency (50Hz) elastic shear wave is generated by a trans-
ducer and then propagates through the tissues. The speed
of propagation is proportional to the stiffness of the crossed
tissue and its measurement can, through specific software,
provide values of liver stiffness expressed in kilopascal (kPa)
[16]. The final value is the median of 10 valid measurements.
TE is painless and rapid and thus highly acceptable to
patients. The volume of liver studied with this method is a
cylinder of 1 × 4 cm length, therefore 100 times bigger than a
sample taken by liver biopsy.
TE has already been incorporated in the international
guidelines for CHB andCHC for pretreatment fibrosis assess-
ment [17, 18] and it has also been evaluated as a potential tech-
nique to predict the presence and degree of portal hyperten-
sion [19, 20] and HCC [21].
In ARFI (acoustic radiation force impulse), the elastogra-
phy system is integrated on an ultrasound machine, allowing
the operator to select the site of liver stiffness measurement
(LSM) through a real-time B-mode ultrasonography and
localize the shear wave avoiding vessels and ribs.
This technique showed a similar accuracy when com-
pared to Fibroscan [22–24] in detecting fibrosis and/or cir-
rhosis.The range ofmeasured values is narrower than Fibros-
can, while quality criteria for ARFI have not yet been
established.
The supersonic shear imaging (SSI) or Shear Wave Elas-
tography is also built on a US device but, while ARFI is based
on the emission of a single pulse wave, in SSI the trans-
ducer emits several wave fronts at increasing depth, with a
frequency band ranging from 60 to 6000Hz.
It generates real-time color mapping of the elasticity,
which is integrated in a standard B-mode image, allowing a
quantitative representation of the tissue elasticity. The final
value will be the average of many obtained by selecting the
region of measurement with guidance from both the B-mode
and SWE images [25].
Magnetic resonance elastography (MRE) combines the
ability of elastography to provide information about liver
tissue texture to the advantages of MR, which allows the
assessment of the entire liver rather than a small part [26].
The main limitation of all the above noninvasive liver
fibrosis tests is the absence of uniformly established and
validated cut-offs for different disease etiologies and fibrosis
stages.
3. Noninvasive Diagnosis of NASH
3.1. Liver Enzymes. Both serum levels of aspartate amino-
transferase (AST) and alanine aminotransferase (ALT) may
increase in patients with NAFLD and this is more prominent
for ALT rather than AST [27]. However, the increase is not
proportionate to the liver inflammation or fibrosis and it is
well documented that patients with significant fibrosis may
present with normal transaminases [28].
Data from different studies report a low accuracy for ALT
levels in predicting NASH, with an area under the curve
(AUC) of 0.6 [29, 30]. Reducing the upper limit of normal
cut-off value for ALT from 30 to 19U/L showed an improve-
ment of sensitivity in a cohort of 233 patients undergoing
bariatric surgery, but at the expense of specificity [31].
3.2. Cytokeratin 18. In the last ten years, emerging data sug-
gested that hepatocellular apoptosis, a genetically determined
form of cell death,may have a significant role in the transition
from simple steatosis to NASH [32]. Within the apoptotic
process, various caspases are activated with the subsequent
cleavage of different substrates.Themain substrate in the liver
is cytokeratin 18 (CK-18), which is an intermediate filament
protein.
In total there have beenmore than eight studies exploring
the diagnostic accuracy of CK-18 fragments levels in NASH.
The main issue is that the cut-offs for diagnosis of NASH
varied among studies; therefore this remains an unvalidated
test [6]. In a cohort of 139 patients with biopsy-proved
NAFLD compared to 155 healthy controls, CK-18 fragments
levels independently predicted the presence of NASH (AUC
0.83) with a sensitivity of 0.75 and specificity of 0.9 [33].
Similar results were obtained by the same group in a cohort
of 201 pediatric patients [34].
In a recent study, involving a multiethnic population of
424 patients, CK-18 fragments levels showed a high specificity
forNAFLDandfibrosis but a limited sensitivity/specificity for
NASH (58%/68%) [35].
Therefore, CK-18 is not an adequate screening tool to
discriminate NASH or early fibrosis in NAFLD patients.
3.3. PIIIPN. Terminal peptide of procollagen III (PIIIPN),
involved in fibrogenic processes, was evaluated in a single
validation study on 136 subjects with NAFLD (71 in vali-
dation cohort) as marker of NASH and developing fibrosis.
Although its performance was promising, with an AUC of
0.85–0.87, further validation studies in larger cohorts are
needed [36].
3.4. Panel Tests. NASH diagnostic is a proprietary test which
encompasses serum levels of cleaved CK-18, adiponectin, and
resistin. It was tested in a cohort of 101 patients that also
included a validation group of 32 patients and showed a
moderate reliability for discriminating NASH from simple
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steatosis (AUC of 0.85 and 0.73 in the derivation and
validation cohort, resp.) [15].
The same panel was reevaluated in an independent
sample of 79 patients and had a suboptimal AUC of 0.7.
Thus, a new model was subsequently developed by the same
group, namely, the NASH diagnostic panel that consists of
presence of diabetes, gender, BMI, serum triglycerides, CK-
18 fragments, and total CK-18 levels. Although the AUC
was greater (0.8) than those for NASH diagnostics or CK-18
fragment levels alone (0.7 and 0.71, resp.) [37], this test needs
further validation in independent cohorts.
TheNashTest comprises 13 serumand clinical parameters,
namely, total bilirubin, GGT, 𝛼2-macroglobulin, apolipopro-
tein A1, haptoglobin, age, gender, weight, height, AST, serum
glucose, triglycerides, and cholesterol, and divides patients
into three categories: not NASH, borderline NASH, and
NASH [38]. NashTest showed a low sensitivity but high speci-
ficity in diagnosing NASH with an AUC ranging between
0.7 and 0.83 [38]. NashTest was also used in patients with
hyperlipidaemia andmorbid obesity and showedAUCs of 0.8
and 0.77, respectively, for the diagnosis ofNASH [39, 40].This
test needs external validation in independent cohorts.
NAFIC score was derived and validated in a cohort of
117 and 442 Japanese biopsy-proven NAFLD patients [41].
The score, ranging from 0 to 4, was calculated considering
cut-off values for serum ferritin, serum fasting insulin, and
serum type collagen 7s. The AUC for predicting NASH was
0.85 and 0.78 in the estimation group and validation group,
respectively [41].
In a backward validation study published in 2013, Naka-
mura et al. showed that the sensitivity of the NAFIC score for
diagnosing NASH could further improve by adding different
insulin levels (AUC 0.8, Se 72.0, Sp 62, PPV 62, and NPV
72%) [42]. Therefore, NAFIC score is promising but requires
further validation.
3.5. Imaging Techniques. In a small study of 58 patients,
magnetic resonance elastography (MRE) was highly accurate
(AUC = 0.93) for discriminating patients with NASH from
those with simple steatosis, with a sensitivity of 94% and
a specificity of 73% [43]. Further validation is required,
considering that MRE is costly and not widely available in
routine clinical practice.
4. Noninvasive Staging of Liver Fibrosis
4.1. AST/ALT Ratio. TheAST/ALT ratio is a simple noninva-
sive test that can detect cirrhosis with a reasonable accuracy
as shown in patients with chronic hepatitis C [44]. Although
data in patients with NAFLD are scarce, it is widely available
and could be used in primary care. However, alcohol use
should be excluded, as patients with alcoholic steatohepatitis
would get a false positive result [45].
4.2. Ferritin. Ferritin is the primary tissue iron-storage in
the liver but also an acute-phase protein; therefore it can be
induced in both cases of iron overload and inflammatory
systemic diseases [46].
Hyperferritinemia is prevalent in about 30% of subjects
with NAFLD and can be the only altered laboratory parame-
ter.
Whether high ferritin levels in patients with NAFLD are
an expression of hepatic inflammation rather secondary to
insulin resistance or represent true iron overload is still not
clarified [47].
Indeed patients withNAFLDoften havemild tomoderate
hepatic iron accumulation, and phlebotomies may improve
insulin resistance [48–50].
Therefore, serum ferritin has also been proposed as a
marker of both NASH and liver fibrosis.
In a study of 628 patients with NAFLD, serum ferritin
levels greater than 1.5 times the upper value of normal were
independent predictors of advanced fibrosis [51].
In another study of 482 patients with NAFLD, although
hyperferritinemia was common, the extent of elevation did
not correlate with the histological stage [52].
In a study of 1201 patients with biopsy-proven NAFLD,
serum ferritin levels increased with increasing histological
grade of steatosis, lobular inflammation, and ballooning;
however its diagnostic performance for detecting presence of
fibrosis was suboptimal (AUC of 0.6, 0.57, and 0.55 for detect-
ing fibrosis, severe fibrosis, and advanced fibrosis, resp.) [53].
The above data suggest that serum ferritin cannot be used
as a biomarker for NASH or fibrosis on its own; however
it is incorporated in panels for liver fibrosis assessment as
discussed later.
4.3. APRI. The aspartate aminotransferase to platelet ratio
index (APRI) has been proposed as a simple test for staging
fibrosis in several chronic liver diseases, firstly in CHC [54].
APRI has been designed to detect significant fibrosis
(METAVIR ≥F2) and cirrhosis with dual cut-offs in both
stages. Studies in patients with NAFLD are scarce compared
to other diseases and have not always used the recommended
cut-offs [55].
In a recent study involving 358 patients with biopsy-
proven NAFLD, the sensitivity and specificity of APRI with
a cut-off >1 for significant fibrosis were, respectively, 30 and
93% [56]. Therefore APRI, similar to other simple noninva-
sive panels, could be used to exclude significant fibrosis.
4.4. BARD. BARD score includes body mass index (BMI),
AST/ALT ratio, and diabetes and has been designed to detect
significant fibrosis (Brunt score ≥F3) [57].
Its main limitation is its high false positivity, based on the
overestimation of BMI and presence of diabetes.
Using a cut-off point≥2 the sensitivity for the detection of
advanced fibrosis was between 86.8 and 100%while the speci-
ficity ranged from 32.5% to 34.7% in different studies [57–59].
Subsequently, an enhanced model of BARD was
attempted by adding INR to the panel. This was tested in
a small cohort of 107 patients and resulted in an improved
composite score for sensitivity and specificity (AUC 0.88
versus 0.8) [59].
In a population of 242 NAFLD patients, the BARD score
had the lowest specificity, sensitivity, Youden index, and
predictive values for predicting both significant fibrosis and
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cirrhosis when compared with other (simple and complex)
models for diagnosis of liver fibrosis [60].
4.5. NAFLD Fibrosis Score. NAFLD fibrosis score was con-
structed and validated in a population of 733 patients with
NAFLD for detecting significant fibrosis (Brunt score ≥F3).
It consists of age, hyperglycemia, BMI, platelet count,
albumin, and AST/ALT ratio and has dual cut-offs.The AUC
for significant fibrosis is 0.88 and 0.82, with sensitivity of 81%
and 77% and specificity of 77 and 71% applying the low cut-
off score, and sensitivity of 51 and 43% and specificity of 98
and 96% applying the high cut-off score in the estimation
and validation group, respectively [61]. Therefore, this score
can be used to triage patients in primary care, as it accurately
diagnoses patients without significant fibrosis.
4.6. FIB-4. The FIB-4 index was developed as a noninvasive
panel to detect significant fibrosis in subjects with HIV-
HCV coinfection and it has been independently validated in
subjects with HCV infection [62, 63].
FIB-4 consists of age, AST, ALT, and platelet count.
Similar to the NAFLD fibrosis score it has dual cut-offs, that
is, a low cut-off of 1.45 with a high sensitivity and a high cut-
off of 3.25 with a high specificity.
FIB-4 has showed a better accuracy in diagnosing
advanced fibrosis in NAFLD patients when compared to
other simple noninvasive tests in several studies (overall AUC
0.88) [64, 65].
Both the NAFLD fibrosis score and FIB-4 can be used in
the primary care as triaging tests, in order to decide which
patients do not have advanced fibrosis and therefore can be
safely managed there.
4.7. Hepascore. Hepascore is a proprietary test that includes
age, gender, bilirubin, gamma-glutamyl transferase (GGT),
hyaluronic acid, and 𝛼2-macroglobulin [66].
This scoring systemhas been tested inNAFLDpopulation
in a study of 242 patients. In comparison with other serum
biomarkers and complex scores [60] it apparently had a good
diagnostic accuracy for staging fibrosis (AUC, sensitivity, and
specificity of 0.73, 50.5%, and 88.3% for stage≥F2, 0.81, 75.5%,
and 84.1% for stage ≥F3, and 0.9, 87%, and 89% for cirrhosis,
resp.). In another study it was showed that its reliability may
vary depending on the influence of fasting on hyaluronic acid
values [67].
4.8. ELF Test. The enhanced liver fibrosis (ELF) test is a
simplified version of the original ELF (OELF) panel whose
diagnostic performance has been validated for a variety of
liver disorders [68].
ELF test is an algorithm that consists of hyaluronic acid
(HA), amino-terminal propeptide of type III procollagen
(PIIINP), and tissue inhibitor of metalloproteinase 1 (TIMP-
1).
In the first validation study in a NAFLD/NASH pop-
ulation of 196 patients for the staging of liver fibrosis, the
ELF panel had good performance in distinguishing severe
fibrosis (stages 3-4) with an AUC of 0.9, but lower AUCs for
moderate fibrosis and absence of fibrosis (0.82 and 0.76, resp.)
[69]. Similar findings were confirmed in NAFLD pediatric
populations [70, 71].
4.9. FibroTest and FibroMeter. FibroTest is a biomarker of
liver fibrosis initially validated in patients with chronic hep-
atitis C [72]. It consists of bilirubin, haptoglobin, GGT, 𝛼2-
macroglobulin, and apolipoprotein-A and classifies patients
into 3 categories, namely, presence/absence of a certain stage
of fibrosis or indeterminate values. Approximately a third of
the patients have values in the indeterminate range [73].
The FibroMeter NAFLD score is a proprietary panel of
serummarkers that has shown a high diagnostic accuracy for
the staging of fibrosis [74]. In a study of 235 NAFLD patients,
the AUCs for the FibroMeter NAFLD score were 0.94 for
significant fibrosis (≥F2), 0.93 for severe fibrosis (F3), and 0.9
for cirrhosis, with high sensitivity, specificity, PPV, and NPV.
It is easily calculated from simple parameters and employing
optimal cut-off values for the diagnosis of significant fibrosis,
97.4% of patients would be correctly classified [75].
All the above proprietary panels need independent val-
idation by groups not involved in their creation and also in
non-Caucasian populations.
4.10. Simple Scores versus Complex Scores. In a multicenter
study of 242 patients, complexmodels (Hepascore, FibroTest,
and FIB-4) were compared to simple models (APRI, BARD).
For the prediction of significant fibrosis (≥F2) all these
models had modest accuracy (AUC 0.71–0.74) with BARD
being least accurate (AUC 0.61,𝑃 < 0.05 versus others), while
Hepascore and FIB-4 had the highest specificity (88.3% and
87.5%, resp.). For the prediction of advanced fibrosis (≥F3),
all complex models provided specificity values >80%, with
Hepascore providing the highest sensitivity (75.5%), while
all models (especially FIB-4 and Hepascore) had a good
accuracy (AUC 0.8–0.86 versus 0.7, 𝑃 < 0.05).
For the prediction of cirrhosis, Hepascore provided the
highest sensitivity (87%). All models had reasonable speci-
ficity (>0.8) except for APRI. Complex scores had the best
accuracy (AUC forHepascore 0.94, FIB-4 and FibroTest 0.86)
[60].
A recent meta-analysis has reported that FibroTest, ELF,
and NAFLD fibrosis scores have significantly better diagnos-
tic accuracy than BARD score and APRI, and their AUCs did
not significantly differ from each other [6].
4.11. Imaging Techniques to Diagnose Fibrosis. Ultrasonogra-
phy, CT scan, andMRI are commonly used in clinical practice
for routine liver imaging. They can detect advanced cirrhosis
with signs of portal hypertension (enlarged spleen and portal
vein, and collateral venous circulation), but not fibrosis of
lesser stages [76, 77].
Transient elastography (Fibroscan) is the most evalu-
ated elastography-based technique for fibrosis assessment in
NAFLD: it has been shown to be an accurate and reproducible
methodology to discriminate patients without any degree of
fibrosis from those with advanced fibrosis or cirrhosis both in
adult and in pediatric NAFLD patients [78, 79].
A meta-analysis of 40 studies showed that elastography
had good sensitivity and specificity for cirrhosis of different
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etiologies and less accuracy for lesser degrees of fibrosis but
a precise validation of specific stiffness cut-off values for the
various stages of fibrosis is still lacking [16].
Nevertheless this technique has some limitations. It can
give falsely elevated values in certain conditions, such as
acute hepatitis, extrahepatic cholestasis, hepatic congestion,
congestive heart failure, hepatic amyloidosis, and recent food
intake [80]. Moreover, using the conventional M probe, liver
stiffness measurements are uninterpretable in 19% of the
cases and this is mainly due to increased waist circumference
and BMI, as it is frequently the case in patients with NAFLD
[81].
A new dedicated XL probe for obese patients, which
produces lower width shear waves, has been recently created.
XL probe has similar overall diagnostic accuracy when
compared to M probe with an AUC of 0.8–0.83 for fibrosis
≥F2, 0.85–0.87 for ≥F3, and 0.89–0.91 for cirrhosis [82, 83].
However, it generates lower stiffness values than theM probe;
therefore different cut-offs should be used.
When using theMprobe in all patients as first line and the
XLprobe in those failing theMprobemeasurements, 78–84%
of patientswill have reliable liver stiffnessmeasurements [84].
In a recent study, liver stiffness was measured by Fibros-
can, ARFI, and SSI and the results were compared with his-
tological data. Pairwise comparison of AUCs values between
SSI, Fibroscan, and ARFI showed no significant difference in
diagnosing mild fibrosis (≥F1) or cirrhosis (F4). SSI showed
higher accuracy in diagnosing significant fibrosis (≥F2) com-
pared to ARFI and in diagnosing severe fibrosis (≥F3) com-
pared to Fibroscan [23].
Real-time (RT) elastography is another technique of inter-
est, as shown in a cohort of 181 patients, with a diagnostic
accuracy of 0.83–0.96 depending on the assessed fibrosis
stage [85].
In a recent retrospective analysis of 142 patients, MRE
showed good accuracy for the diagnosis of advanced fibrosis
(AUC 0.95) with high sensitivity and specificity (0.85 and
0.93, resp., at a cut-off of 4.15 kPa) [86].These are probably the
best results obtained by a noninvasive diagnostic technique
for the present.
All elastography-based techniques need universally appli-
cable validated cut-offs across different fibrosis stages. This
would require adequately powered prospective studies.
5. Genetic Markers as Potential Future
Noninvasive Prognostic Tests
It has also become increasingly apparent that genetic factors
may influence the development and progression of NASH.
These are polymorphisms of genes that regulate oxidative
damage, the inflammatory cascade, and priming of fibrosis.
The first such polymorphism described was a variant of
patatin-like phospholipase-3 (PNPLA3) (also called adiponu-
trin), derived from an isoleucine-to-methionine substitution
at residue 148 (single-nucleotide polymorphism or SNP).The
GG genotype of PNPLA3 in patients with NAFLD has been
associated with more severe steatosis, presence of NASH,
and fibrosis [87, 88]. Furthermore, it seems to correlate with
an increased risk of atherogenesis and subsequent cardiovas-
cular events [89]. Carriers of the PNPLA3 rs738409 minor
(G) allele have also a higher probability to develop NAFLD-
correlated HCC, especially of the poorly differentiated type
[90].
Another single nucleotide polymorphismwhich has been
recently correlated with the development and prognosis of
NAFLD is a glutamate to lysine amino acid substitution
at residue 167 in transmembrane 6 superfamily member 2
(TM6SF2) sequence; the T allele of this gene is associated
with the development of NAFLD, its progression to fibrosis
and cirrhosis, and also altered cholesterol metabolism [91];
however there are some contradictions in literature and fur-
ther studies are required to validate its role in larger cohorts
of patients [92]. Further potential genetic determinants of
NAFLD and progression of liver fibrosis are being evaluated
in genome-wide association studies and may be used in the
future as noninvasive prognostic indicators.
6. Conclusions
For the present several noninvasive diagnostic strategies have
been proposed as alternatives to liver biopsy in patients with
NAFLD, with various levels of diagnostic accuracy. Although
the accurate diagnosis of NASH is still not possible with
available noninvasive tools, there are several scores that can
diagnose advanced fibrosis (≥F3). Simple panels, such as FIB-
4 and NAFLD fibrosis score, are easily computable, have
a high negative predictive value for advanced fibrosis, and
have been validated against clinical outcomes.Therefore they
could be used as first line test to “rule out” patients without
advanced fibrosis and thus prevent unnecessary secondary
care referrals in a significant number of patients.
More refined noninvasive tests such as Fibroscan, Hep-
ascore, FibroMeter, FibroTest, or ELF could be used as
second tier tests to further characterize patients, although
this sequential approach needs prospective validation. The
development and validation of such noninvasive algorithms
will likely limit the need for liver biopsy in a selected few in
the near future.
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